Advertisement

Topics

Companies Related to "A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer" [Most Relevant Company Matches] RSS

19:33 EDT 23rd October 2018 | BioPortfolio

Here are the most relevant search results for "A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer" found in our extensive corporate database of over 50,000 company records.

Showing "Safety Tolerability Study 24781 Subjects With Cancer" Companies 1–25 of 4,200+

Relevant

PharmaTech Solutions Inc

PTS was founded in 1999 by a group of pharmaceutical research professionals who believed that a pioneering approach was required to solve the industry’s study enrollment problems. Through innovation and excellence, PTS has amassed the technology and experience to develop patient recruitment solutions that identify and address the core issues that can hinder enrollment. PTS understands that findi...


CEL-SCI Corporation CEL-SCI Corporation

CEL-SCI's work is focused on finding the best way to activate the immune system to fight cancer and infectious diseases. Its lead investigational immunotherapy, Multikine* (Leukocyte Interleukin, Injection), is currently being studied in a pivotal Phase 3 clinical trial as a potential neoadjuvant treatment for patients with squamous cell carcinoma of the h...

TheraCoat

TheraCoat is a specialty pharmaceutical company founded in 2004 by uro-oncologists and biomaterial specialists. TheraCoat’s Board of Directors and Scientific Advisory Board feature renowned scientific experts in the fields of urology, pharma top executives and experienced business veterans; among them Prof. Belldegrun and Mr. Hurvitz, both TEVA Board ...


Sonus Pharmaceuticals

SONUS PHARMACEUTICALS is focused on the development of drugs that provide better therapeutic alternatives for cancer patients,including improved efficacy,safety and tolerability,and are more convenient to use

Biothera

Biothera, a privately held U.S. biotechnology company, is developing Imprime PGG, a late clinical stage biologic that modulates the immune response to cancer. Data from the most recent randomized phase 2 study of Imprime PGG in first line non-squamous non-small cell lung cancer (NSCLC) was featured as a late-breaking abstract in the Immunotherapy of Cancer...

The Finnish Breast Cancer Group

The study, led by the Finnish Breast Cancer Group, was a large open-label, two-arm, randomised multicentre phase III study in women with early breast cancer. 1,500 patients in Finland and Sweden with no distant metastases who had an intermediate to high risk of recurrence within five years from the time of diagnosis, were recruited to the study.

Protalex, Inc.

Protalex, Inc. is a clinical stage biopharmaceutical company that is developing a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, including but not limited to, rheumatoid arthritis. Protalex’s lead product PRTX-100, which is formulated with a highly-purified form of staphylococcal protein A, has completed a Phase 1b...

Cytheris SA

Cytheris is a privately held clinical-stage biopharmaceutical company focused on research and development of therapies for immune modulation.  These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV, HCV, and HBV or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transp...

Pharmacon Research GmbH

Pharmacon Research is an independent contract research organization (CRO) with headquarters in Berlin and clinical sites in Prague, Warsaw, Bratislava and Budapest. Founded in 1992 by the management of a successful Phase I unit, Pharmacon Research focuses on specific Phase I studies in patients and symptomatic subjects and on early Phase II studies (dose finding, proof of concept). Irrespective of...

Sonus Pharmaceuticals, Inc.

Headquartered near Seattle, Washington, Sonus Pharmaceuticals, Inc. is focused on the development of cancer drugs that are designed to provide better efficacy, safety and tolerability, and ease of use. Sonus moved an oncology product candidate, SN2310, into a Phase 1 clinical trial in September 2006. For additional information on Sonus, including past news releases, please visit http://www.son...

International Pharmaceutical Research Center

International Pharmaceutical Research Center the commitment to unparalleled Quality Research. Our strength is our recognition from sponsors, investigators, and study subjects in conducting each study with dedication and a personal touch, while maintaining strict compliance with good clinical practice.

nTouch Research Corporation

nTouch Research Corporation is a leading provider of Phase II-IV clinical trials services delivering investigator selection, patient recruitment and study management services for pharmaceutical, CRO, and biotechnology industries.nTouch owns and operates 16 highly-rated research centers across the USA serving 250 private practice investigators. Our strength is our commitment to sponsors, investigat...

Clinical Research Associate

Clinical Research Associate, also known as a Monitor, is an individual that oversees the progress and conduct of a clinical trial. A clinical trial is usually implemented by physicians at a hospital, clinic, or physician's office. The CRA is required to oversee the initiation, progress, and conduct of the clinical trial to ensure the scientific integrity of the data collected, and the protection o...

Advanced Biomedical Research Incorporated

Advanced Biomedical Research, Inc. (ABR) Corporate Headquarters is located in Pennington, New Jersey adjacent to the Princeton biopharmaceutical research corridor. ABR is a full service CRO offering an integrated package of customized services including clinical study protocol design, project management and study monitoring, quality assurance auditing, medical safety monitoring, biostatistics and...

ADVANCED VIRAL RESEARCH CORP

Advanced Viral Research Corp. (OTC Bulletin Board: ADVR), established in the mid-1980s, and headquartered in Yonkers, New York, is a biopharmaceutical firm dedicated to improving patients' lives by researching, developing, and bringing to market new and effective therapies for many serious diseases and disorders. With the commitment of expert leadership and skilled research scientists, ADVR is ag...

PreScience Labs, LLC

PreScience is a developmental stage bio-pharmaceutical company focused on the development of anti-cancer drugs. It has successfully completed preclinical mechanistic, in vitro and animal testing using intra-arterial delivery of its proprietary drug PSL-001. The FDA approved immediate enrollment of a Phase I, dose-escalating study, which PreScience intends ...

Winston Pharmaceuticals, Inc.

Winston is a pharmaceutical company focused on pain control which is developing products for large pain control markets, as well as for niche markets, where there are still significant unmet needs for pain management options with improved efficacy, safety, and tolerability profiles. Winston's late stage product candidates include osteo- and rheumatoid arth...

Roskilde University

Roskilde University is a state university founded in 1972 with the objective of providing research and education at the highest level in the fields of natural science, social science and the humanities. These activities at Roskilde University are organised in ten departments; degrees are offered in a wide range of subjects at Bachelor, Master and Ph.D. levels.Many study programmes are now being of...

Atlantic Life Sciences, Inc

Atlantic Life Sciences, Inc., Provider of Tailored Clinical Services ALS Inc. is located in Montreal.It is one of the world-class CRO where the Experience, the Expertise and the Strategic Project Management create a value addition for the study success. Since its inception, Atlantic Life Sciences Inc. accomplishes clinical studies with a top quality. Each study is unique. Since 2003, ALS Inc. cond...

Nagourney Cancer Institute

The Nagourney Cancer Institute is a clinical research center that has pioneered the study of human tumor tissue for individualized cancer patient drug selection and has facilitated cancer drug discovery.

Opsona Therapeutics Limited

Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including autoimmune and inflammatory diseases, transplant rejection, cancer, diabetes, Alzheimer's disease and atherosclerosis. The company was founded in 2004 ...

RWTH Aachen University

RWTH Aachen University,Here, you will discover numerous opportunities offered at this university in the areas of research, teaching and study.The RWTH Aachen is characterised by its strength in science and engineering education. It also provides a wide range of subjects in Economics, Arts and Humanities and Medicine with an emphasis on intensive interaction between all disciplines. The focus on in...

Jennerex, Inc.

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in two mid-stage clinical trials in patients with primary liver cancer -- an international, randomized, Phase 2 dose-response clinical trial, and a Phase 2 study in combina...

The German Breast Group and Celgene Corporation

GBG is a large independent academic network of over 500 study centers in Germany with the world- wide largest experience in conducting neoadjuvant breast cancer trials. Since 1998, with joined forces from AGO-B, over 10.000 patients participated in the neoadjuvant “Gepardo” trial series. GBG has recruited at totality of over 35.000 patients to tr...

Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the development of small-molecule therapeutics for the treatment of gout, cancer and human immunodeficiency virus (HIV). RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, is a selective URAT1 transporter inhibitor in Phase 2 clinical development. Our next-generation URAT1 inhib...


More From BioPortfolio on "A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks